GORE RECEIVES FDA APPROVAL FOR BREAKTHROUGH ENDOVASCULAR DEVICE IN COMPLEX AORTIC ANEURYSMS
First off-the-shelf solution for treatment of complex aneurysmal disease involving the visceral aorta.
Jan 25, 2024
GORE ANNOUNCES FIRST PATIENT IMPLANT IN THE ARISE II PIVOTAL STUDY OF THE GORE<sup>®</sup> ASCENDING STENT GRAFT
CAUTION: Investigational device. Limited by United States law to investigational use.
Dec 20, 2023
THE GORE RELIEF CLINICAL STUDY BEGINS RANDOMIZING PATIENTS TO EVALUATE PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF
CAUTION: Investigational device. Limited by United States law to investigational use.
Oct 15, 2023
GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE® VIAFORT VASCULAR STENT ILIOFEMORAL STUDY
CAUTION: Investigational device. Limited by United States law to investigational use.
Jun 6, 2023
GORE ANNOUNCES FIRST U.S. ENROLLMENT FOR THE GORE<sup>®</sup> VIAFORT VASCULAR STENT IVC STUDY
CAUTION: Investigational device. Limited by United States law to investigational use.
Mar 28, 2023
GORE INITIATES THE RELIEF CLINICAL STUDY EVALUATING PFO CLOSURE FOR MIGRAINE HEADACHE RELIEF
CAUTION: Investigational device. Limited by United States law to investigational use.
Nov 1, 2022
Gore Completes First In-human Implants of the GORE® VIAFORT Vascular Stent
CAUTION: Investigational device. Limited by United States law to investigational use.W. L. Gore & Associates initiates its GORE® VIAFORT Device Pivotal Clinical Study for the treatment of inferior
Oct 28, 2022